tirzepatide 5 mg/0.5 ml ALI-TIRZEP 5MG 1) receptor agonist Mounjaro 5 mg/0.6 mL Tirzepatide

x 1978 2023 , y 0 2,500

M., Thomas, T., et al

Consult medical experts for mood shift support

However, the impact of GLP-1 RAs on mortality and cardiovascular outcomes in patients with T2DM and Heart failure with reduced ejection fraction (HFrEF) remains uncertain

These drugs also have low uptake (less than 2% in the USA) due to several factors, including patients reluctance to seek treatment, lack of addiction training among healthcare providers and considerable stigma surrounding AUD and addiction. - Lorenzo Leggio, et al, Nature Medicine, December 2023 Based on the percentage of people in the United States with alcohol use disorder (11% or ~29.5 million) and the number of people who have received medication for alcohol use disorder in the past year (624,000) and the number of people taking GLP-1 drugs (7 percent of American adults or 18 million), we roughly estimate that more than 3 times as many people with AUD have been incidentally prescribed a GLP-1 in the past year than have been prescribed a medication that is FDA indicated for alcohol use disorder (~2 million vs 624,000, and these groups may overlap)

Mounjaros most common side effects include nausea, diarrhoea, and bloating, which can overlap with symptoms from gallbladder removal